

NUTRI.023A



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
AUG 09 2002
TECH CENTER 1008/2900
PATENT

Applicant : Komorowski et al.) Group Art Unit: 1008/2900
)
App. No. : 10/090,038)
)
Filed : February 27, 2002)
)
For : CHROMIUM/BIOTIN TREATMENT)
OF DYSLIPIDEMIA AND DIET-)
INDUCED POST PRANDIAL)
HYPERGLYCEMIA)
)
Examiner : Unknown)
)

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

A certification under 37 C.F.R. § 1.97(e) is set forth below regarding reference Nos. 13, 14, 20, and 23.

Appl. No. : 10/090,038
Filed : February 27, 2002

CERTIFICATION UNDER 37 C.F.R. § 1.97(e)(1)

I hereby certify that reference Nos. 13, 14, 20, and 23 contained in this Statement were first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this Information Disclosure Statement.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 08/01/02

By: Mallory K. de Merlier

Mallory K. de Merlier
Registration No. P-51,609
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(619) 235-8550

S:\DOCS\MKD\MKD-2839.DOC\060302